HELP Cybin Inc. Common Stock
USHealthcareAs of 2026-07-02
Why HELP matters now
Cybin Inc. Common Stock (HELP) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.24 with -0.64% on the session and $312.2M in market capitalization; recent performance reads 1-month +11.72% and YTD -42.91%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-42.6M, and EPS of $-1.76. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -100.2%.
The latest indexable market news headline is "Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $22.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.71
P/S
0.00
EV/EBITDA
0.69
DCF Value
$4.26
FCF Yield
-100.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-61.1%
ROA
-43.0%
ROIC
-44.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-42.6M | $-1.76 |
| Q2 2026 | $0.00 | $-47.0M | $-1.94 |
| Q1 2026 | $0.00 | $-24.6M | $-1.10 |
| Q4 2025 | $0.00 | $-30.6M | $-1.46 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$22.00
Target (Median)
$22.00
Target Range
$22.00 - $22.00
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
0.70
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.